01-01-2016 | Topic Paper
Immune checkpoint inhibitors: a new frontier in bladder cancer
Published in: World Journal of Urology | Issue 1/2016
Login to get accessAbstract
Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.